Structure Therapeutics Inc.

NASDAQ:GPCR

Biotechnology

Healthcare
$17.36 +0.86%

+$0.39 today

Market cap
$999.36M
Beta
-1.42
P/E (TTM)
-19.3
EPS (TTM)
-$2.35
52W Low $15.80High $94.90

Volume 1.10M

Average 0.87M

GPCR Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Structure Therapeutics Inc.NASDAQ: GPCR

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $182.13M (cash outflow) rose 195.4% year over year, ahead of the +62.6% change in trailing-twelve-month net income. Sequentially, it rose 139.0% from the prior quarter. Over 3 fiscal years it compounded at +40.1% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$87.09M (-38.3%) for the fiscal year ending Dec 2026, a slowdown from the +15.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$182.13M+139.0% QoQ
Last fiscal yearDec 2025
-$141.2M+15.2% YoY
LTMJun 2026
-$291.03M+62.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+195.4%-72.2%-267.6 pp
1 year+15.2%-38.3%-53.6 pp
3-year CAGR+40.1%-35.4%-75.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(141.2M) USD
Year-over-year change
-15.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GPCR compares with its peers on the latest reported figures

  • GPCR's LTM Jun 2026 net income of $291.03M is the 2nd largest of the 8 companies compared; the peer median is $89.93M.
  • Its year-over-year change of +62.6% is the 3rd highest of 7, against a peer median of +13.5%.
  • Over three fiscal years its annual growth of +40.1% compares with a peer median of +19.2%.
GPCR Competitors Peer median
Net Income for GPCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$349.58M +83.2%+73.1%—
GPCRStructure Therapeutics Inc.LTM Jun 2026$291.03M +62.6%+40.1%—
KLRAKailera Therapeutics, Inc.FY2025$148.96M ———
MAZEMaze Therapeutics, Inc.LTM Mar 2026$122.54M -335.9%+4.5%612.7%
BIOABioAge Labs, Inc.LTM Mar 2026$89.93M +26.6%+26.6%871.8%
SEPNSepterna, Inc.LTM Sep 2026$59M +0.3%+20.9%61.3%
BMEABiomea Fusion, Inc.LTM Mar 2026$44.95M -65.1%-8.9%—
VTVTvTv Therapeutics Inc.LTM Mar 2026$918K +104.2%+17.5%2.5%
Peer median (excluding GPCR) $89.93M+13.5%+19.2%337.0%

Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(38.05M)(51.32M)(89.62M)(122.53M)(141.2M)
Depreciation & Amortization72K277K295K992K1.33M
Deferred Income Tax00000
Stock-Based Compensation1.49M2.51M8.19M18.79M28.99M
Change in Working Capital4.06M2.97M6.97M2.96M(88.27M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.9M2.15M(859.25K)3.31M4.77M
Other Working Capital2.17M815K7.83M(343K)(93.05M)
Other Non-Cash Items268K(558K)(5.32M)(16.86M)(23.05M)
Operating Cash Flow(32.16M)(46.12M)(79.49M)(116.64M)(222.2M)
Capital Expenditures(1.21M)(155K)(2.17M)(1.29M)(3.61M)
Acquisitions (Net)00000
Purchases of Investments(4.21M)(123.45M)(416.99M)(702.52M)(547.38M)
Sales of Investments23.28M61.5M151.05M344.9M630.54M
Other Investing Activities00(231.38K)010.25M
Investing Cash Flow17.86M(62.11M)(268.34M)(358.91M)89.8M
Debt Repayment00000
Common Stock Issued00472.3M514.57M767.18M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(104K)(2.49M)(20.77M)690K(4.66M)
Financing Cash Flow103.25M29.01M451.53M515.26M762.52M
Effect of Forex Changes0000(1.66M)
Net Change in Cash88.95M(79.21M)103.7M39.72M630.12M
Free Cash Flow(33.37M)(46.28M)(81.66M)(117.93M)(225.81M)

Structure Therapeutics Inc.

NASDAQ:GPCR

Intrinsic Alpha fair value

Locked

Current Price

$17.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.